EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Protectin D1 and maresin 1 attenuate airway hyperreactivity induced by IL‐13 in human isolated small bronchi

Willem Abma iD, Sven-Erik Dahlén, Craig E Wheelock, Mikael Adner, Mamdoh Al-Amerie, Erik Sachs, Kasra Vali Jalali, Leonardo De Maria, Henric Olsson, Jesper Säfholm iD

British Journal of Pharmacology · 2026

DOI: 10.1111/bph.70298 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, 2026. Verfasst von Willem Abma und 9 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Integrative Metabolomics, The Institute of Environmental Medicine, Karolinska Institutet, Solna, Sweden. Hauptthemen laut MEDLINE: Interleukin-13, Bronchi, Docosahexaenoic Acids, Bronchial Hyperreactivity. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Heart-Lung Foundation, Swedish Research Council (Vetenskapsrådet Medicin), Tore Nilsons Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Interleukin (IL)‐13 is implicated in airway hyperreactivity (AHR), a key feature of asthma. We explored the potential anti‐AHR activity of selected specialised pro‐resolving mediators (SPMs) in IL‐13‐induced AHR models, using human bronchial smooth muscle cells (BSMCs) and human isolated bronchi. Experimental Approach Calcium flux responses induced by histamine or LTD 4 were assessed in BSMCs preconditioned with IL‐13 and SPMs for 24 h. Human bronchi were isolated from lung tissue and preconditioned for 48 h in the presence or absence of IL‐13 and SPMs. Concentration‐response relationships for histamine and LTD 4 were established using myography to determine efficacy ( E max ) and potency (pEC 50 ) following interventions. Key Results In BSMCs, exposure to IL‐13 increased calcium flux ( E max ) triggered by histamine and LTD 4 . Protectin D1 (PD1) and maresin 1 (MaR1) reversed this effect, but not lipoxin A 4 , resolvin D2, and maresin‐conjugate in tissue repair 3 (MCTR3). In bronchi, IL‐13 exposure amplified contractions to histamine and LTD 4 , and this enhancement was reversed by PD1 and MaR1. In contrast, PD1 and MaR1 added acutely during myography had no effect on agonist‐induced contractility. PD1 attenuated IL‐13–induced enhancement of airway contractions triggered by mast cell activation. CysLT 1 antagonism did not influence the anti‐hyperreactive effect of SPMs. Chemo‐informatics revealed structural similarities between PD1 and MaR1 that may explain the anti‐hyperreactive action of these two SPMs. Conclusion and Implications This new anti‐hyperreactive action of PD1 and MaR1 encourages further research into their potential as therapies for the treatment of airway hyperreactivity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-13BronchiDocosahexaenoic AcidsBronchial HyperreactivityHumansMyocytes, Smooth MuscleHistamineCells, CulturedMaleFemaleDose-Response Relationship, DrugCalciumMiddle AgedIn Vitro Techniques

Stichwörter der Autor:innen

Type 2 inflammationairway smooth musclehyperresponsivenessleukotrieneslipid mediatorsresolutionspecialised pro‐resolving mediators

Substanzen

Interleukin-13Docosahexaenoic Acids7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoic acidprotectin D1HistamineCalcium

Autor:innen und Institutionen

  • Unit of Integrative Metabolomics, The Institute of Environmental Medicine, Karolinska Institutet, Solna, Sweden.
  • Department of Respiratory Medicine and Allergy and Center for Molecular Medicine, Karolinska University Hospital, Solna, Sweden.
  • Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Clinical Lung and Allergy Research Unit, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
  • Unit of Experimental Asthma and Allergy Research, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Division of Thoracic Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.

ORCID-Profile: Willem Abma, Jesper Säfholm

Förderung

  • Swedish Heart-Lung Foundation
  • Swedish Research Council (Vetenskapsrådet Medicin)
  • Tore Nilsons Foundation
  • Magnus Bergvalls Foundation
  • Konsul Th C Berghs Foundation
  • Åke Wibergs Foundation
  • Cayman Biomedical Research Institute (CaBRI)
  • Lars Hiertas Minne

Zitieren

APA

Abma, W., Dahlén, S. E., Wheelock, C. E., Adner, M., Al-Amerie, M., Sachs, E., Vali Jalali, K., De Maria, L., Olsson, H., & Säfholm, J. (2026). Protectin D1 and maresin 1 attenuate airway hyperreactivity induced by IL‐13 in human isolated small bronchi. British Journal of Pharmacology. https://doi.org/10.1111/bph.70298

Vancouver

Abma W, Dahlén SE, Wheelock CE, Adner M, Al-Amerie M, Sachs E, et al. Protectin D1 and maresin 1 attenuate airway hyperreactivity induced by IL‐13 in human isolated small bronchi. British Journal of Pharmacology. 2026. doi:10.1111/bph.70298

BibTeX
@article{Abma2026,
  author = {Abma, Willem and Dahlén, Sven-Erik and Wheelock, Craig E and Adner, Mikael and Al-Amerie, Mamdoh and Sachs, Erik and Vali Jalali, Kasra and De Maria, Leonardo and Olsson, Henric and Säfholm, Jesper},
  title = {Protectin D1 and maresin 1 attenuate airway hyperreactivity induced by IL‐13 in human isolated small bronchi},
  journal = {British Journal of Pharmacology},
  year = {2026},
  doi = {10.1111/bph.70298}
}
Kostenlos starten →